Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published January 2021 | Accepted Version
Journal Article Open

How haematopoiesis research became a fertile ground for regulatory network biology as pioneered by Eric Davidson

Abstract

Purpose of review: This historical perspective reviews how work of Eric H. Davidson was a catalyst and exemplar for explaining haematopoietic cell fate determination through gene regulation. Recent findings: Researchers studying blood and immune cells pioneered many of the early mechanistic investigations of mammalian gene regulatory processes. These efforts included the characterization of complex gene regulatory sequences exemplified by the globin and T-cell/B-cell receptor gene loci, as well as the identification of many key regulatory transcription factors through the fine mapping of chromosome translocation breakpoints in leukaemia patients. As the repertoire of known regulators expanded, assembly into gene regulatory network models became increasingly important, not only to account for the truism that regulatory genes do not function in isolation but also to devise new ways of extracting biologically meaningful insights from even more complex information. Here we explore how Eric H. Davidson's pioneering studies of gene regulatory network control in nonvertebrate model organisms have had an important and lasting impact on research into blood and immune cell development. Summary: The intellectual framework developed by Davidson continues to contribute to haematopoietic research, and his insistence on demonstrating logic and causality still challenges the frontier of research today.

Additional Information

© 2020 Wolters Kluwer Health, Inc. We thank the late Eric H. Davidson for many critical, stimulating discussions. Relevant support for EVR was from USPHS grants R01HL119102 and R01HD100039 and the Ruddock Professorship at Caltech. Research in the BG laboratory is supported by Wellcome, MRC, Cancer Research UK, NIH-NIDDK and Blood Cancer UK. Conflicts of Interest: EVR is a member of the Scientific Advisory Board for Century Therapeutics and has been a consultant for A2 Biotherapeutics. BG has been a consultant for Autolus, and the BG lab has received funding from Astra Zeneca, Novo Nordisk and Autolus.

Attached Files

Accepted Version - nihms-1651632.pdf

Files

nihms-1651632.pdf
Files (879.6 kB)
Name Size Download all
md5:985ac0963e088b528df4ce6e41171704
879.6 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
December 22, 2023